CClinicalTrials.gg
RecruitingNCT06199856Updated Mar 14, 2025

Assessment System for Sarcopenia Based on Ultrasonographic Data

An observational study in Sarcopenia and Ultrasound, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged Up to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by West China Hospital · Observational

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500
Ages
Up to 100 Years
Sex
All
01

Study summary

  1. To develop an artificial intelligence assisted diagnostic model for sarcopenia based on ultrasound images;
  2. To develop artificial intelligence classification and regression models for auxiliary diagnosis of sarcopenia, patient strength estimation, and other functions based on ultrasound image data.
Read the detailed description

Sarcopenia is a syndrome of age-related muscle mass loss and muscle function decrease, which can be comorbid with a variety of diseases and interacts extensively with various disease states to influence disease prognosis. Diseases such as cancer, diabetes, chronic kidney disease, and rheumatoid arthritis can accelerate the process of muscle loss by affecting myogenic cell regeneration, interfering with protein synthesis, increasing protein consumption, and enhancing protein degradation by the ubiquitination pathway, and the decline in motor function will, in turn, further worsen the prognosis of the disease. Despite some regional differences, the prevalence of sarcopenia has been found to exceed 10%. Early identification of the potential risk of sarcopenia and early intervention in the early stages of muscle mass and function impairment is one of the most important steps to improve the quality of life of older adults.

Currently, the diagnosis of sarcopenia relies on three features: loss of muscle mass, loss of muscle strength, and loss of physical performance. At present, physicians usually use bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) to determine skeletal muscle mass index SMI to measure muscle mass, grip strength test to measure muscle strength, gait speed or tools such as SPPB scores to assess physical performance. A diagnosis of sarcopenia can be made when a subject experiences a decrease in SMI combined with a decrease in grip strength or a decrease in gait speed.

In the field of medical imaging, researchers have been working to explore and validate appropriate imaging tools and markers to diagnose and evaluate sarcopenia. The common methods for deep mining of medical imaging include radiomics and machine learning, usually by analyzing the texture features of muscles at specific sites to quantify muscle function or segmenting skeletal muscles accurately in two dimensions or three dimensions to quantify muscle mass. Compared to computed tomography (CT) or magnetic resonance imaging (MRI), ultrasound is a more accessible and less costly medical imaging technique, especially in low- and middle-income regions. Ultrasound can be used to conveniently scan local muscles and obtain muscle characteristics such as muscle thickness, cross-sectional area, and pennation angle. Our previous studies have demonstrated that SMI in older adults can be accurately estimated by using muscle thickness at four sites together with basic information such as age and body mass index (BMI), and have found in cross-regional validation that the stability of estimates can be maintained across communities with very different ethnic proportions. However, several existing large studies on ultrasound in sarcopenia are currently focusing only on muscle morphological measurements, ignoring the large amount of hidden ultrasound image information. At the same time, the flexibility of the scanning process has led to greater resistance from radiomics or deep learning tools to use the images for artificial intelligence classification than CT or MRI.

Fronted with such a dilemma, we attempted to establish an intelligent risk grading system for sarcopenia, based on multidimensional data including basic information such as age and BMI, ultrasound measurements, and original image content, to complete the risk grading of sarcopenia in older adults in a one-stop manner, so as to realize the rapid screening and classification of potential sarcopenia populations for further clinical management.

02

Conditions studied

  • Sarcopenia
  • Ultrasound

Browse trials for

03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 120 across 419 observational studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The older adults with risk of sarcopenia

Inclusion criteria

  • > 50 years of age
  • Patients with suspected sarcopenia, for example, who needed assistance with walking, rising from a chair, or climbing stairs; recently had a history of falls walking; recent unintentional weight loss

Exclusion criteria

Exclusion Criteria:

  • Amputated arm or leg
  • Severe oedema (oedema higher than knee level)
  • Implantable pacemaker
  • Impaired consciousness, poor general health, or other reasons that would prevent the individual from completing the study
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Hospitalized older adults at risk of sarcopenia

    Diagnostic Test: ultrasound scan

  • Community-dwelling older adults at risk of sarcopenia

    Diagnostic Test: ultrasound scan

Interventions

  • Diagnostic testultrasound scan

    ultrasound scan

06

What researchers measure

Primary outcomes

  1. Death

    Time frame: Within 2 years after the initial ultrasound examination

  2. Diagnosed sarcopenia

    Skeletal muscle mass index (SMI)\<7 (men) /5.7 (women)kg/m2 (measured by BIA) and gait speed\<1m/s or grip strength\<28kg (men)/18kg (women)

    Time frame: Within 2 years after the initial ultrasound examination

07

Study locations

1 of 1 sites recruiting
  • Xinyi Tang
    Chengdu, Sichuan, China
    • Xinyi Tang, Dr. · Contact · +8615680819215
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — By submitting an application to the project leader via email and obtaining approval from relevant hospital departments

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06199856
Lead sponsor
West China Hospital
Responsible party
Xinyi Tang (Principal Investigator, West China Hospital) — Principal investigator
First posted
Jan 10, 2024
Start date
Oct 1, 2020
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 14, 2025

Study contacts

Xinyi Tang, Dr.
Contact
tangxinyi1996@outlook.com
+8615680819215
Xinyi Tang, Dr.
principal investigator · Department of Medical Ultrasound, West China Hospital, Sichuan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion